LAMEA Human Growth Hormone Market, by Application, by Distribution Channel, by Country, Industry Analysis and Forecast, 2019 - 2025

The Latin America, Middle East and Africa Human Growth Hormone Market is expected to witness market growth of 9.4% CAGR during the forecast period (2019-2025).

Excessive release of growth hormones induces pituitary tumor, consisting of the anterior pituitary somatotroph cells. Such somatotroph cells are healthy and grow slowly, releasing excess growth hormones. This causes headaches, blurred vision due to pressure on the optic nerves, other hormonal deficiencies, and thickening of the bones of the jaw, toes, and fingers, which ultimately results in jaw heaviness and an increase in the size of the digits called acromegaly.

Growth hormone (GH) is a substance in the body that helps children grow and mature. It is made by a pituitary gland, which is a small gland between the lobes of the brain. Growth Hormone Deficiency (GHD) is a well-known clinical condition in adults. It is characterized by defects in the metabolism of the substrate, body composition, physical and psychosocial functioning, all of which increase after GH replacement.

Turner Syndrome is an uncommon chromosomal disorder that harms females and is defined by a partial or complete loss of one of the X chromosomes. Symptoms of Turner syndrome are a wide neck and low or indistinct hairline, vulnerability to high blood pressure, minor eye problems, eyelid drops, and underactive thyroid gland. The age of diagnosis dropped significantly with a greater understanding of Turner Syndrome in the medical community, which, in turn, is fueling the market. As it is associated with several complications related to heart disease, autoimmune disorders, hearing loss, mental health problems, infertility and pregnancy complications, the demand for growth hormone treatment is rising.

Based on Application, the market is segmented into Small for Gestational Age, Prader-Willi Syndrome, Idiopathic Short Stature, Turner Syndrome, Growth Hormone Deficiency and Other Applications. Based on the type of Growth Hormone Deficiency, the application of Human Growth Hormone is studied across Pediatric Growth Hormone Deficiency and Adult Growth Hormone Deficiency. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy, Specialty Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck Group, Teva Pharmaceuticals Industries Ltd., Ipsen Pharma Biotech SAS, Novartis AG (Sandoz International GmbH), Pfizer, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Ferring Holdings SA, Novo Nordisk A/S, Eli Lilly and Company, and Anhui Anke Biotechnology Group Co., Ltd.

Scope of the Study

Market Segmentation:

By Application

• Small for Gestational Age
• Prader-Willi Syndrome
• Idiopathic Short Stature
• Turner Syndrome
• Growth Hormone Deficiency and
• Pediatric Growth Hormone Deficiency
• Adult Growth Hormone Deficiency
• Other Applications

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Specialty Pharmacy
• Online Pharmacy

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Companies Profiled

• Merck Group
• Teva Pharmaceuticals Industries Ltd.
• Ipsen Pharma Biotech SAS
• Novartis AG (Sandoz International GmbH)
• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
• Ferring Holdings SA
• Novo Nordisk A/S
• Eli Lilly and Company
• Anhui Anke Biotechnology Group Co., Ltd.

Unique Offerings from the Publisher

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free